Express News | Maxin Biotech and MGI Tech have reached a strategic cooperation agreement.

BreakingsMay 6 17:41

MGI Tech (688114): Continuous narrowing of losses; full-read-length sequencing business expected to recover

Event: The company recently released its 2025 annual report and the first-quarter report for 2026. In 2025, it achieved operating revenue of 2.78 billion yuan, representing a year-on-year decrease of 7.73%. Net profit attributable to shareholders was -222 million yuan, showing a year-on-year decline.

Pacific SecuritiesMay 5 00:00

MGI Tech (688114): Rapid Growth in Sequencing Equipment Installation Continues, Quality Enhancement and Efficiency Improvement Progressing Orderly

Event: The company released its financial performance for the first quarter of 2025 and 2026. In 2025, it achieved revenue of 2.78 billion yuan (year-over-year decrease of 7.73%) and a net loss attributable to shareholders of 222 million yuan, with the loss narrowing. Non-recurring net profit attributable to shareholders...

Huayuan SecuritiesApr 28 13:57

Nomura Adjusts MGI Tech's Price Target to 52.46 Yuan From 84.98 Yuan, Keeps at Neutral

MT NewswiresApr 28 13:11 · Ratings

MGI Tech (688114): Revenue growth resumed in 1Q26, with continued reduction in losses.

The company announced its financial results for 2025 and the first quarter of 2026: 1) Revenue/net profit attributable to shareholders/non-recurring net profit for 2025 were RMB 2.78 billion, -RMB 222 million, and -RMB 390 million, respectively, representing year-on-year changes of -7.7%, +63.0%, and +40.2%.

Huatai SecuritiesApr 28 07:47

MGI Tech (688114): Performance remains overall stable, comprehensively strengthening competitiveness in gene sequencing business.

The company’s 2025 performance met our expectations, while its 1Q26 results exceeded our forecasts. The company announced its 2025 and 1Q26 financial results: revenue for 2025 was RMB 2.78 billion (-7.73% YoY); net loss attributable to shareholders.

CICCApr 27 20:16